Ozempic / Wegovy (GLP-1) Leads
Reach patients who suffered severe gastrointestinal injuries and other serious side effects from semaglutide-based GLP-1 receptor agonist medications.
Ozempic / Wegovy GLP-1 Litigation
Ozempic and Wegovy, both semaglutide-based GLP-1 receptor agonists manufactured by Novo Nordisk, have been linked to severe gastrointestinal side effects that were not adequately disclosed on product labeling. Patients prescribed these medications for diabetes or weight loss have reported gastroparesis, bowel obstruction, and pancreatitis, among other serious conditions. Lawsuits allege the manufacturer failed to warn about the full scope and severity of these risks.
Associated Conditions
- Gastroparesis (stomach paralysis)
- Bowel obstruction
- Pancreatitis
- Gallbladder disease
- Intestinal blockage
- Severe nausea and vomiting requiring hospitalization
- Ileus (intestinal dysfunction)
Claimant Eligibility
- Prescribed Ozempic, Wegovy, or other semaglutide-based medication
- Experienced severe gastrointestinal side effects during or after use
- Required hospitalization or emergency treatment due to side effects
- Diagnosed with gastroparesis, bowel obstruction, or pancreatitis
- Side effects occurred while using or shortly after discontinuing the medication
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Running a Ozempic / Wegovy (GLP-1) mass tort marketing campaign
Common questions from law firms about Ozempic / Wegovy (GLP-1) lead generation and campaign management.
- What does a Ozempic / Wegovy (GLP-1) mass tort marketing campaign include?
- A Ozempic / Wegovy (GLP-1) mass tort marketing campaign from Mass Tort Marketing Agency covers channel strategy across Meta, Google/PPC, OTT, and mass tort SEO; compliant ad creative; TCPA-verified intake; claimant qualification against your Ozempic / Wegovy (GLP-1) case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- Are Ozempic / Wegovy (GLP-1) leads exclusive to my firm?
- Yes. Every Ozempic / Wegovy (GLP-1) lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Ozempic / Wegovy (GLP-1) claimants qualified before delivery?
- Each Ozempic / Wegovy (GLP-1) claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a TrustedForm or Jornaya consent token captured under the FCC one-to-one consent standard before the lead reaches your intake team.
- How is a Ozempic / Wegovy (GLP-1) campaign priced?
- Campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. You can scale volume up or down by tort as your docket capacity changes.
See how every lead is qualified on our mass tort leads page, or compare providers in our top mass tort marketing firms guide.